|
|
Article: Bard Completes Sale of Its Global Coronary Cath Lab Business to Arterial Vascular Engineering, Inc.
- Article from:
- Business Wire
- Article date:
- October 1, 1998
CopyrightCOPYRIGHT 1998 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MURRAY HILL, N.J.--(BUSINESS WIRE)--Oct. 1, 1998--C. R. Bard, Inc. (NYSE:BCR) today completed the sale of its global coronary cath lab business (angioplasty and angiography) to Arterial Vascular Engineering, Inc. (NASDAQ:AVEI) for $600 million. Bard reported worldwide sales of coronary angioplasty and angiography products of approximately $215 million in 1997. The coronary cath lab business includes manufacturing plants in Billerica, Massachusetts and Galway, Ireland as well as approximately 1900 employees worldwide.
The sale of this business represents another step in a series of strategic initiatives being pursued by the company to enhance Bard's operating ...
Related newspaper, magazine, and journal articles:
|
|
Article: Latest IMV Market Report Shows Continued Investment in ...
Business Wire;
January 8, 2007 ;
700+ words
... ... cases were performed at 1,970 cardiac cath lab sites in 2006. This represents a 9 ... annualized rate of 2% per year. Of these cath lab cases, 89% (3.74 million) are cardiac ... faster pace, with new technology advancing cath lab capabilities," observed Lorna Young ...
|
|